GENO Stock Overview
Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr28.60 |
| 52 Week High | kr66.90 |
| 52 Week Low | kr27.20 |
| Beta | 1.44 |
| 1 Month Change | -10.06% |
| 3 Month Change | -43.48% |
| 1 Year Change | -49.11% |
| 3 Year Change | -38.89% |
| 5 Year Change | 70.75% |
| Change since IPO | -73.27% |
Recent News & Updates
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18
What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28Recent updates
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?
Mar 27How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?
Dec 30Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?
Nov 23
Shareholder Returns
| GENO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -7.4% | -6.1% | -0.7% |
| 1Y | -49.1% | 11.1% | 8.7% |
Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned 10.7% over the past year.
Return vs Market: GENO underperformed the Swedish Market which returned 8.1% over the past year.
Price Volatility
| GENO volatility | |
|---|---|
| GENO Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: GENO's share price has been volatile over the past 3 months.
Volatility Over Time: GENO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 37 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; GingisKHAN, a cysteine protease that digests human IgG1; and FabDELLO, a protease that digests human IgG1.
Genovis AB (publ.) Fundamentals Summary
| GENO fundamental statistics | |
|---|---|
| Market cap | kr1.87b |
| Earnings (TTM) | kr61.50m |
| Revenue (TTM) | kr158.23m |
30.4x
P/E Ratio11.8x
P/S RatioIs GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENO income statement (TTM) | |
|---|---|
| Revenue | kr158.23m |
| Cost of Revenue | kr15.16m |
| Gross Profit | kr143.07m |
| Other Expenses | kr81.57m |
| Earnings | kr61.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 90.42% |
| Net Profit Margin | 38.87% |
| Debt/Equity Ratio | 0% |
How did GENO perform over the long term?
See historical performance and comparison